Von Hippel-Lindau gene expression in human endometrium during menstrual cycle

Lu,Yan-Yan; Zhu,Wei-Jie; Xie,Bao-Guo

doi:10.3892/mmr.2014.1962

Von Hippel-Lindau gene expression in human endometrium during menstrual cycle

Authors:
- Yan-Yan Lu
- Wei-Jie Zhu
- Bao-Guo Xie
View Affiliations

Affiliations: Department of Developmental and Regenerative Biology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, P.R. China
Published online on: February 18, 2014 https://doi.org/10.3892/mmr.2014.1962
Pages: 1355-1358

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The von Hippel‑Lindau (VHL) gene is a tumor suppressor gene, which is widely expressed in the kidney, lung, breast, eye, ovary and cervix. Mutations of the VHL gene are able to induce VHL disease and tumorigenesis. However, it has yet to be evaluated whether the VHL gene is expressed in the human endometrium. The objective of the present study was to investigate whether the VHL gene is expressed in the human endometrium and to identify changes in expression levels during the menstrual cycle. A total of 35 human endometrial tissue samples in the proliferative (n=17) and secretory phase (n=18) were subjected to the present study. VHL gene expression levels were assessed using Western blot analysis and reverse transcription polymerase chain reaction (RT-PCR). It was observed that the expression of VHL mRNA in the human endometrium decreased from the proliferative to secretory phase (P<0.05). Levels of VHL protein in the proliferative phase were higher than those in the secretory phase (P<0.05). In conclusion, the present study revealed that the VHL gene is expressed in the normal human endometrium, and its expression levels change during the different periods of the menstrual cycle.

View Figures

View References

1	Maas JW, Groothuis PG, Dunselman GA, de Goeij AF, Struyker Boudier HA and Evers JL: Endometrial angiogenesis throughout the human menstrual cycle. Hum Reprod. 16:1557–1561. 2001. View Article : Google Scholar : PubMed/NCBI
2	Uz YH, Murk W, Yetkin CE, Kayisli UA and Arici A: Expression and role of interleukin-23 in human endometrium throughout the menstrual cycle and early pregnancy. J Reprod Immunol. 87:21–27. 2010. View Article : Google Scholar : PubMed/NCBI
3	Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W and Geil L: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 260:1317–1320. 1993. View Article : Google Scholar : PubMed/NCBI
4	Kamada M, Suzuki K, Kato Y, Okuda H and Shuin T: von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res. 61:4184–4189. 2001.PubMed/NCBI
5	Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM and Oldfield EH: von Hippel-Lindau disease. Lancet. 361:2059–2067. 2003. View Article : Google Scholar : PubMed/NCBI
6	Pavlova TV, Kashuba VI, Muravenko OV, Yenamandra SP, Ivanova TA, Zabarovskaia VI, Rakhmanaliev ER, Petrenko LA, Pronina IV, Loginov VI, Iurkevich OIu, Kiselev LL, Zelenin AV and Zabarovskiĭ ER: Technology of analysis of epigenetic and structural changes of epithelial tumors genome with NotI-microarrays by the example of human chromosome. Mol Biol (Mosk). 43:339–347. 2009.(In Russian).
7	Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, Ota M, Katsuyama Y, Mellilo G and Konishi I: Expression of hypoxia-inducible factor 1α, hypoxia-inducible factor 2α, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1α is an independent prognostic factor in ovarian carcinoma. Hum Pathol. 38:1310–1320. 2007.
8	Choi CH, Lee KM, Choi JJ, Kim TJ, Kim WY, Lee JW, Lee SJ, Lee JH, Bae DS and Kim BG: Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. Cancer Lett. 255:26–33. 2007. View Article : Google Scholar : PubMed/NCBI
9	Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 13:680s–684s. 2007. View Article : Google Scholar : PubMed/NCBI
10	Kamada M, Suzuki K, Kato Y, Okuda H and Shuin T: von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res. 61:4184–4189. 2001.PubMed/NCBI
11	Noyes RW, Herting A and Rock J: Dating the endometrial biopsy. Am J Obstet Gynecol. 122:262–263. 1975.PubMed/NCBI
12	Richards FM, Schofield PN, Fleming S and Maher ER: Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet. 5:639–644. 1996. View Article : Google Scholar : PubMed/NCBI
13	Tang N, Mack F, Haase VH, Simon MC and Johnson RS: pVHL function is essential for endothelial extracellular matrix deposition. Mol Cell Biol. 26:2519–2530. 2006. View Article : Google Scholar : PubMed/NCBI
14	Xu JY, Zhu WJ, Cao XZ, Li XF and Wu J: Aberrant expression of the von Hippel-Lindau gene in human endometrial hyperplasia and endometrial carcinoma. Int J Gynecol Cancer. 21:430–434. 2011. View Article : Google Scholar : PubMed/NCBI
15	Rajakumar A, Doty K, Daftary A, Markovic N and Conrad KP: Expression of von Hippel Lindau (pVHL) protein in placentae from normal pregnant women and women with preeclampsia. Placenta. 27:411–421. 2006. View Article : Google Scholar : PubMed/NCBI
16	Datta K, Mondal S, Sinha S, Li J, Wang E, Knebelmann B, Karumanchi SA and Mukhopadhyay D: Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. Oncogene. 24:7850–7858. 2005. View Article : Google Scholar : PubMed/NCBI
17	Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM and Ganapathi R: von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 180:860–865. 2008. View Article : Google Scholar : PubMed/NCBI
18	Nayak NR and Brenner RM: Vascular proliferation and vascular endothelial growth factor expression in the rhesus macaque endometrium. J Clin Endocrinol Metab. 87:1845–1855. 2002. View Article : Google Scholar : PubMed/NCBI
19	Critchley HO, Osei J, Henderson TA, Boswell L, Sales KJ, Jabbour HN and Hirani N: Hypoxia-inducible factor-1α expression in human endometrium and its regulation by prostaglandin E-series prostanoid receptor 2 (EP2). Endocrinology. 147:744–753. 2006.
20	André H and Pereira TS: Identification of an alternative mechanism of degradation of the hypoxia-inducible factor-1α. J Biol Chem. 283:29375–29384. 2008.
21	Genbacev O, Krtolica A, Kaelin W and Fisher SJ: Human cytotrophoblast expression of the von Hippel-Lindau protein is downregulated during uterine invasion in situ and upregulated by hypoxia in vitro. Dev Biol. 233:526–536. 2001. View Article : Google Scholar : PubMed/NCBI
22	Kaloglu C and Onarlioglu B: Extracellular matrix remodelling in rat endometrium during early pregnancy: the role of fibronectin and laminin. Tissue Cell. 42:301–306. 2010. View Article : Google Scholar : PubMed/NCBI
23	Li Z, Kreiner M, van der Walle CF and Mardon HJ: Clustered integrin α5β1 ligand displays model fibronectin-mediated adhesion of human endometrial stromal cells. Biochem Biophys Res Commun. 407:777–782. 2011.
24	Zhou Q, Pardo A, Königshoff M, Eickelberg O, Budinger GR, Thavarajah K, Gottardi CJ, Jones J, Varga J, Selman M, Sznajder JI, Raj JU and Zhou G: Role of von Hippel-Lindau protein in fibroblast proliferation and fibrosis. FASEB J. 25:3032–3044. 2011. View Article : Google Scholar : PubMed/NCBI